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Abstract
Protease-activated receptor-2 is widely expressed in mammalian epithelial, immune and neural tissues. Cleavage of PAR2 by
serine proteases leads to self-activation of the receptor by the tethered ligand SLIGRL. The contribution of other classes of
proteases to PAR activation has not been studied in detail. Cathepsin S is a widely expressed cysteine protease that is
upregulated in inflammatory conditions. It has been suggested that cathepsin S activates PAR2. However, cathepsin S
activation of PAR2 has not been demonstrated directly nor has the potential mechanism of activation been identified. We
show that cathepsin S cleaves near the N-terminus of PAR2 to expose a novel tethered ligand, KVDGTS. The hexapeptide
KVDGTS generates downstream signaling events specific to PAR2 but is weaker than SLIGRL. Mutation of the cathepsin S
cleavage site prevents receptor activation by the protease while KVDGTS retains activity. In conclusion, the range of actions
previously ascribed to cysteine cathepsins in general, and cathepsin S in particular, should be expanded to include
molecular signaling. Such signaling may link together observations that had been attributed previously to PAR2 or
cathepsin S individually. These interactions may contribute to inflammation.
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Introduction
Protease-activated receptors (PARs) comprise a family of G-
protein-coupled receptors that are self-activated following proteo-
lytic cleavage of their extracellular N-terminal domains. The PAR
family consists of four members, PAR1, PAR2, PAR3 and PAR4,
that are expressed in epithelial, immune, neural and vascular
tissues and have been implicated in inflammation, pain, itch,
hemostasis, thrombosis and carcinogenesis[1,2]. Given their wide
distribution and involvement in numerous physiologic and
pathophysiologic conditions, the importance of understanding
how these receptors are activated and subsequently regulated, and
whether they can be targeted for therapeutic purposes, continues
to grow.
PAR2 signaling has been implicated in the development of
inflammatory and bowel diseases, asthma, itch and pain. The
receptor is expressed on many types of cells including keratino-
cytes, sensory neurons, fibroblasts, endothelial cells, and inflam-
matory cells[2,3]. Consistent with this broad expression, PAR2 is
involved in numerous physiologic and pathophysiologic processes
in response to both endogenous and exogenous proteases. PAR2
has been shown to be activated by several families of proteases
expressed in the skin, including serine proteases (e.g. kallikreins 5
and 7, mast cell tryptase) and the cysteine protease, cathepsin
S[4,5]. PAR2 may also act as a sensor for exogenous protease
activity, with in vitro data supporting activation by a cockroach
allergen and the dust mite allergen der p 1[6], gingipain from a
gingivitis-inducing bacterium[7], and the plant proteases mucu-
nain, papain, bromelain and ficin amongst others[8].
Proteases cleave the extracellular N-terminal domain of PARs.
This cleavage generates a new N-terminus and unmasks a tethered
ligand that triggers intracellular signaling[9,10]. Synthetic hex-
apeptides corresponding to the first six amino acids of the newly
formed N-terminus can serve as ligands for PARs. This action is
independent of receptor cleavage[11–13] although micromolar
concentrations of hexapeptide are needed for activity. It has been
suggested that synthetic hexapeptides or different proteases acting
on the same PAR may stimulate different downstream signaling
pathways[14] but little is known about the specific cleavage sites
and resultant ligands produced by different proteases.
To better understand the mechanisms of PAR2 activation and
regulation, we sought to identify cleavage sites and downstream
signaling events induced by an endogenous cysteine protease,
cathepsin S. Cysteine cathepsins, including cathepsin S, have been
broadly implicated in health and disease including inflammation,
cardiovascular and pulmonary disease, obsesity, itch and pain[15].
Cathepsin S is unique among cysteine proteases in that its
expression is up-regulated by IFN-c, which supports a role in
inflammation[16]. Cathepsin S is expressed in many types of cells.
It has a broad pH profile. It is active at neutral pH, consistent with
extracellular biological activity[16]. Cathepsin S is a potent
elastase and is critical to antigen presentation as it cleaves the Ii
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mechanism in a mouse model of inflammatory bowel disease and
evokes itch when applied to human skin, potentially as a result of
PAR2 activation[5,20]. These observations support the possibility
that cathepsin S cleaves PAR2 but the cleavage site(s) involved in
activation of this receptor have not been identified.
We demonstate that cathepsin S cleaves the N-terminus of
PAR2 at a site distinct from that of serine proteases. Substitution of
a single residue near the N-terminus prevents cathepsin S from
activating the receptor. KVDGTS, a hexapeptide derived from
the newly exposed N-terminal sequence, retains activity on the
wildtype and mutant receptors. Cathepsin S and KVDGTS
activate downstream signaling in keratinocytes and a heterologous
cell line. The results presented here reveal that cathepsin S can
participate in signal transduction via activation of PAR2.
Materials and Methods
Cell culture
HeLa cells were obtained from the ATCC and maintained in
DMEM supplemented with fetal bovine serum (Fisher Biochem-
icals), L-glutamine, penicillin and streptomycin. Normal human
epidermal keratinocytes (NHEKs) were harvested from neonatal
foreskin and maintained in Keratinocyte Serum-Free media
supplemented with epidermal growth factor, bovine pituitary
extract, L-glutamine, penicillin and streptomycin. All reagents
were obtained from Invitrogen unless otherwise noted.
PARs, Peptides and proteases
cDNA for human PAR2 was obtained commercially and cloned
into pcDNA3.1(2). The superscript number following the first
amino acid of the peptides corresponds to the position in full
length PAR2. Several peptides were synthesized by Peptide 2.0
(Chantilly, VA): G
28TNRSSKGRSLIGKVDGTSHVTGKGVT
represents 27 N-terminal residues of PAR2 following processing.
K
41VDGTS and I
39GKVDG are PAR2 cleavage peptides and
S
46HVTGK is a downstream control peptide. The conventional
serine protease tethered ligand hexapeptide SLIGRL served as a
positive control and the reverse peptide, LRGILS as a negative
control. SLIGRL is derived from the sequence of murine PAR2
but is used as opposed to SLIGKV in both human and mouse
studies of PARs. S
37LIGKVDGTS and the KVDGTS reverse
peptide, STGDVK, were synthesized by GenScript (Piscataway,
NJ).
Recombinant human cathepsin S was produced as follows. The
human cathepsin S proprotein coding region was isolated by PCR
using the forward and reverse primers GCGCCATGGTGGCA-
CAGTTGCATAAAGATCCTAC CCTG and GCGCTCGAG-
CTAGATTTCTGGGTAAGAGGGAAAGCTAG and a tem-
plate of plasmid DNA containing the entire coding sequence of
human cathepsin S. The PCR product was cut with Nco I and
Xho I, and cloned into the pTYB4 expression vector from New
England Biolabs for expression in E.coli. Cells were grown in LB
medium induced with 0.3 mM IPTG, harvested by centrifugation,
resuspended in lysis buffer A (0.5 M NaCl, 0.05 M Tris, 5 mM
EDTA, pH 8.0) and lysed in a French press. The lysate was
centrifuged and the protein was found predominantly in inclusion
bodies which were dissolved in buffer B (10 mM DTT and 8 M
urea), and refolded in the presence of buffer B containing 0.7 M L-
arginine, 0.01 M glutathione, 0.001 M glutathione disulfide, and
0.005 M EDTA as described[21]. The refolded procathepsin S
was concentrated by Minimate Concentrator (Pall Corporation)
and washed three times with buffer A. It was activated after
adjusting to pH 4.5 with acetic acid, adding DTT to 5 mM and
incubating at 37uC for 3 hours. Recombinant cathepsin S was
purified using Centricon Plus-70 membranes (Millipore) with a
MW cut off of 10 kDa, dialyzed against buffer A and aliquoted
and stored at 280uC. SDS-PAGE was used to confirm the
presence of pro and activated human cathepsin S based on
predicted MW. The specific activity of cathepsin S was assayed
using Z-VVR-AMC in fluorimetric and Z-FR-pNA in colorimetric
assays[22] and determined to be 10,000 mU/mg protein.
Cathepsin S digestion of the human PAR2 N-terminal
peptide
A peptide comprising the N-terminus of PAR2,
GTNRSSKGRSLIGKVDGTSHVTGKGVT, was dissolved in
50 mM Tris, pH 7.0, 0.1 M NaCl, 0.1 mM EDTA, and 0.01%
Tween-20 to a concentration of 100 mM. 100 mL of this solution
was incubated with cathepsin S (1 mM final concentration) at 37uC
for 20 minutes. Acetonitrile and formic acid were added to final
concentrations of 2% and 0.1%, respectively, and the material was
immediately frozen at 280uC. The reaction samples were
analyzed by the Harvard Microchemistry & Proteomics Analysis
Facility (Cambridge, MA). Label-free quantitation based on
spectral counting has been shown to be a reliable technique.
After digestion with a proteolytic enzyme (trypsin or others) the
number of peptide-spectrum matches (PSMs) observed during an
LCMS analysis correlates well with relative protein abundances in
the sample[23,24].
The LC/MS/MS system was configured with a nanoAcquity
UPLC (Waters, Milford MA) running 0.1% formic acid in water
(A-buffer) and 0.1% formic acid in acetonitrile (B-buffer) using self-
packed glass capillary 100 m ID Integrafrit trapping column and
75 m ID Picofrit analytical columns (New Objective, Woburn MA)
packed with 5 cm of 5 u Magic C18AQ and 20 cm of 3 m Magic
C18AQ (Michrom Bioresources) respectively. Sample trapping
was performed at 2 ul/min followed by the analytcal gradient at
0.3 m/min. The gradient started after 15 minutes of trapping, and
proceeded from 2%B to 52%B/10 minutes.
The mass spectrometer used was a LTQ-Orbitrap XL (Thermo
Fisher Scientific, San Jose, CA) with full MS acquired in profile
mode in the Orbitrap at 60,000 resolution across the mass range of
395–1600 Da, using a common background ion as an internal
calibrant (445.120025 Da, polycyclosiloxane). From the full scan,
the top 4 ions by intensity were selected for MS/MS in the linear
ion trap with a relative collision energy of 35%. Samples were
diluted 1:10 with 0.1% formic acid in water (A-buffer) and 1 ml
injected onto the LC/MS/MS system. Tandem mass spectra were
searched with SEQUEST against the Uniprot Sprot database
followed by direct searching of the sequences of PAR2. Data
processing was performed in a custom version of Proteomics
Browser Suite (PBS) v2.8 (ThermoFisher Scientific). PSMs were
accepted with a mass tolerance of ,1 ppm and score threshold to
meet an estimated false discovery rate of ,1% using a reverse
decoy database strategy. Sf for each peptide is a single score
calculated in PBS by a neural network with Xcorr, DeltaCn, Sp,
RSp, peptide mass, charge state, and database size as inputs.
Calcium imaging
Human PAR2 cDNA was cloned as an Xho I-Hind III
fragment (1206 bp) into pcDNA3.1(2). 10 mg of DNA were
diluted into 0.5 ml of DMEM and mixed with 0.5 ml of DMEM
containing 10 ml of Lipofectamine 2000 transfection reagent and
incubated at room temperature for 20 minutes. HeLa cells were
grown to confluence, trypsinized and 1610
6 cells were pelleted in
a 15 ml tube by centrifugation at 1000 rpm for 5 minutes. The
DMEM-Lipofectamine 2000-DNA mixture (1 ml) was added to
PAR2 Activation by Cathepsin S
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temperature for 20 minutes. Four ml of complete DMEM with
10% FBS were added to the tube, mixed by inverting the tube
several times, plated into a 96-well glass bottom plate at
20,000 cells/well, and placed in a 37uCC O 2 incubator. HeLa
cells transfected with vector alone or salmon sperm DNA (shown
in the figures) were plated as a control. The medium was aspirated
two days after transfection. Fura-2 was used as a ratiometric
calcium-sensitive indicator as follows. 100 ml of complete DMEM
containing 2 mM of Fura-2 were added to each well and left at
room temperature in the dark for 1 hr. Following loading with
Fura-2, the medium was aspirated and replaced with 90 mlo f
HEPES-buffered saline (20 mM HEPES, 115 mM NaCl, 5.4 mM
KCl, 2 mM CaCl2, 0.8 mM MgCl2, 13.8 mM glucose, pH 7.4).
Imaging was performed using a Zeiss Axiovert 200 M
microscope platform equipped with a flipping filter wheel for
ratiometric imaging. Axiovision software, version 4.6 was used for
image analysis of the cells which were excited at 340 nm and
380 nm. Ten ml of peptide agonist were added at 20 seconds after
the start of the excitation procedure. Images were taken every 5
seconds, including at zero time, during a 3-minute period or
longer if required. The software later analyzed all images taken
during each excitation period. Typically, ratiometric changes were
measured in 10–20 cells in each image. An average of the
fluorescence of the cells in each image was calculated and plotted
against time in seconds.
Concentration-effect measurements for peptides
HeLa cells transfected with PAR2 cDNA were subjected to
ratiometric imaging as described above with PAR2 peptides,
SLIGRL, KVDGTS, and SLIGKVDGTS in addition to the
reverse peptides LRGILS and STGDVK at concentrations from
1 nM - 1 mM. Each of the concentration-dependent readings was
performed in triplicate. Maximum intensities at each of the
dilutions were calculated and plotted against concentration using
GraphPad/PRISM software version 6.0 (Irvine, CA). Error bars
represent +/2SEM.
Preparation of Gaussia luciferase-PAR2 fusion cDNAs
Gaussia luciferase cDNA was cloned, without its termination
codon, into pcDNA3.1(2) as an Xho I-EcoR I fragment. Human
PAR2 cDNA and its mutants, M1, M2 and M3, were generated
using PCR primers designed to start after the signal sequence and
end with a termination codon: GCGGAATTCATCCAAG-
GAACCAATAGATCCTCTAAAG and GCGAAGCTTTCAA-
TAGGAGGTCTTAACAGTGGTTGAACTTG. The PCR am-
plified cDNAs were cloned into EcoR I and Hind III sites C-
terminal to Gaussia luciferase cDNA. The resulting plasmids were
called pGLPAR2, pGLPAR2M1, pGLPAR2M2 and pGLPAR2M3.
Generation of PAR2 N-terminal mutants to remove
cathepsin S cleavage sites
The QuickChange site-directed mutagenesis procedure (Agilent
Technologies, Santa Clara, CA) was used to generate PAR2 N-
terminal mutants. PAR2M1, with a single amino acid change, was
created by substituting the leucine
38 codon, CTT, with alanine,
GCT, using the primers: PAR2M1F, CTAAAGGAAGAAGC-
GCTATTGGTAAGGTTGATG, and PAR2M1R, CATCAA-
CCTTACCAATAGCGCTTCTTCCTTTAG. PAR2M2 was
generated by substituting the glycine
40 codon nearest leucine
38,
GGT, with alanine, GCT, using the primers: PAR2M2F, GGAA-
GAAGCCCTATTGCTAAGGTTGATGGCAC and PAR2M2R,
GTGCCATCAACCTTAGCAATAGGGCTTCTTCC. The
PAR2M3 mutant incorporated both of these amino acid substitutions. It
was generated using the primers: PAR2M3F, CTCTAAAGGAA-
GAAGCGCTATTGCTAAGGTTGATGGCACATC, PAR2M3R,
andGATGTGCCATCAACCTTAGCAATAGCGCTTCTTCCTT-
TAGAG.Super coiled plasmid DNA containing human PAR2 cDNA as
aX h oI - H i n dI I If r a g m e n ti np c D N A 3 . 1( 2) was used as the template in
the PCR procedure.
Gaussia luciferase assay
The plasmid DNAs pGLPAR2, pGLPAR2M1, pGLPAR2M2
and pGLPAR2M3 (10 mg of each) were transfected into 2610
6
HeLa cells as described above and plated into 10 cm dishes. HeLa
cells transfected with salmon sperm were used as controls. Forty-
eight hours after transfection, the cells were washed twice with
PBS, scraped and pelleted. Cells were scraped in order to
eliminate the use of trypsin, which could activate PARs, and
allowed for the luminescence assay to be performed in a small
volume. Pelleted cells were resuspended into 200 ml PBS, and
100 ml of each was incubated with cathepsin S at a final
concentration 2 mM for 10 minutes at room temperature.
Untreated cells were processed by the same methods for a
negative control. Cathepsin activity was diluted by the addition of
300 ml of complete DMEM. Cells were pelleted and supernatants
collected. Luminescence assays were performed in triplicate on
50 ml of the supernatants according to the instructions of the
manufacturer (New England Biolabs, Ipswich, MA).
Inositol phosphate (IP)assay
To determine the effect of PAR2 activation on Gq stimulation,
we measured IP1, a downstream metabolite of IP3, using the IP-
One HTRF assay from Cis Bio, Medford, MA. HeLa cells were
transfected with salmon sperm DNA or PAR2 cDNA as described
above, plated in 10 cm culture dishes and incubated at 37uC with
5% CO2. After 24 hours, the cells were trypsinized, counted,
plated into 96-well plates at 80,000 cells/well and incubated for
another 24 hours. The medium was replaced with a stimulation
buffer containing LiCl, per the instructions of the manufacturer.
Ligands, including cathepsin S (1 mM), KVDGTS (100 mM) and
SLIGRL (10 mM) were added to wells and incubated at 37uC for
1 hour and IP1 levels determined. This assay was performed on
multiple wells containing each ligand on three occasions. Error
bars represent SEM.
Western blot analysis for Gaussia luciferase
HeLa cells were transfected and treated with cathepsin S as
described for the luciferase assay. After treatment with cathepsin S,
cells were pelleted at 14,000 rpm for 3 minutes. Supernatants
(100 ml) were collected and denatured with 1 ml of 10% SDS.
Equal volumes of supernatants were prepared in loading buffer,
heated at 90uC for 5 minutes, run on NuPAGE Novex Bis-Tris
mini gels and transferred to nitrocellulose membranes using
standard protocols. The blot was probed with a primary rabbit
anti-Gaussia luciferase antibody. HRP-conjugated donkey anti-
rabbit antibody was used to identify the relevant bands on the
membrane.
Western blot analysis for p-PKC (Ser660)
HeLa cells were transfected with PAR2 plasmid DNA as
described above. Untransfected HeLa cells were plated as a
control. Forty-eight hours after transfection, cells were rinsed with
PBS three times. Transfected HeLa cells were incubated with
either SLIGRL (10 mM), SLIGKVDGTS (10 mM), KVDGTS
(100 mM), or cathepsin S (1 mM) at room temperature for 10
PAR2 Activation by Cathepsin S
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(10 mM) in a similar manner. A subset of transfected HeLa cells
remained untreated and served as a negative control. After
incubation, cells were harvested, pelleted and lysed by sequential
freeze-thaw cycles. Cell lysates were centrifuged at 4uC for 15
minutes. Supernatants were collected and protein concentrations
were determined by Bradford assay. Equal amounts of cell lysates
were loaded onto NuPAGE Novex Bis-Tris mini gels, electropho-
resed and transferred to nitrocellulose membranes using standard
protocols. The blot was first probed with rabbit anti-phospho-
PKC (bII Ser660) antibody (Cell Signalling Technology, Danvers,
MA), and later reprobed with a mouse anti-actin antibody to
identify the control actin band at 42 kDa. Primary antibodies were
labeled with HRP-conjugated donkey anti-rabbit antibody and
HRP-conjugated donkey anti-mouse antibody, respectively, fol-
lowed by detection of the position of the antigen on the blot.
Results
Cathepsin S cleaves a synthetic amino terminus of PAR2
It has been suggested previously that cathepsin S activates
PAR2 but this was not demonstrated conclusively and the
potential mechanism of activation was not investigated. Here we
sought to determine the mechanism by which cathepsin S activates
PAR signaling and asked whether, and if so at what sites, this
protease cleaves the N- terminus of PAR2. Cathepsin S was
incubated with a synthetic N-terminal peptide of human PAR2.
Cleavage products were collected and sequenced by tandem mass
spectrometry (MS/MS). Cathepsin S proteolytic activity resulted
in several cleavage points (Table 1). The predominant cleavage
point was after GRSL, exposing the peptide
IGKVDGTSHVTGKGVT. The next most common sequence
results in G at the P1 position followed by
KVDGTSHVTGKGVT. Peptides based on these two sequences
were studied here. Correlations with cathepsin S cleavage points in
the MEROPS database and in a high-content proteomics-based
profile of cathepsin S cleavage[25], including the generation of a
SeqLogo, IceLogo, and HeatMap were not productive given the
short sequences and thus not shown.
PAR2 amino terminal hexapeptides activate the PAR2
receptor
PAR2 signaling is coupled primarily to Gq which leads to
activation of phospholipase C (PLC), the formation of inositol
triphosphate (IP3) and diacylglycerol (DAG) and calcium mobi-
lization. PAR2 activation by the hexapeptide SLIGRL provokes
transient intracellular calcium mobilization in primary keratino-
cytes and various cell lines. We sought to determine whether
hexapeptides based on cathepsin S cleavage of the synthetic N-
terminus of PAR2 could also trigger activation of the receptor.
The hexapeptides KVDGTS and IGKVDG were synthesized
based on the cleavage sites produced in PAR2 following
incubation with cathepsin S as indicated above. The decapeptide
SLIGKVDGTS was also evaluated as it encompasses SLIGRL,
IGKVDG and KVDGTS. The SLIGRL and KVDGTS reverse
peptides, LRGILS and STGDVK respectively, served as controls.
All of these peptides were evaluated for functionality. HeLa cells,
which do not express PAR2 endogenously, were transfected with
PAR2 cDNA or, as a control, salmon sperm DNA. Fura-2 calcium
imaging was performed following treatment with these peptides.
Concentration-effect curves of the peptides on PAR2 transfect-
ed HeLa cells were generated. (Figure 1). The curves for SLIGRL
and SLIGKVDGTS overlapped. The curve for KVDGTS was
shifted to the right and did not achieve as high a peak response as
either SLIGRL or SLIGKVDGTS. The data for IGKVDG is not
included as this peptide is weaker than KVDGTS. Based on these
data, we decided to use SLIGRL at 10 mM and KVDGTS at
100 mM in subsequent experiments. The reverse peptides were
inactive at all concentrations examined.
KVDGTS (100 mM) activated PAR2 with a profile similar to
that for SLIGRL (10 mM) (Figure 2a) and reported previously for
cathepsin S. IGKVDG (100 mM), which partially overlaps with
KVDGTS, induced PAR2 activation but was approximately 50%
less active than KVDGTS. IGKVDG was therefore not used in
further experiments. Neither cathepsin S nor any of the peptides
induced calcium responses in HeLa cells transfected with salmon
sperm DNA alone. Cathepsin S and KVDGTS each activated
NHEKs which endogenously express PAR2 (Figure 2b).
As hexapeptides activate the receptors without cleavage, we
predicted that incubation with a hexapeptide followed by a
protease would still elicit a signal, although perhaps diminished.
To test this hypothesis, HeLa cells transfected with PAR2 were
treated with KVDGTS and subsequently with cathepsin S after
different time intervals (2, 3, 5, 10, 30 and 60 minutes). As
predicted, following treatment with KVDGTS, calcium signals
were present but reduced in response to cathepsin S at all of these
timepoints. The data in Figure 3a represent the interval at 2
minutes and is representative of all timepoints examined. Similar
results were found when KVDGTS was applied followed by
SLIGRL, papain (2 mM) or trypsin (10 nM) (not shown). These
studies were performed at room temperature and receptor
turnover would be expected to be minimal.
In contrast, when cathepsin S, papain or trypsin were applied
first, subsequent treatment with protease, KVDGTS or SLIGRL
failed to induce a calcium response at any time up to 60 minutes
after initial protease treatment. The data for cathepsin S followed
by KVDGTS are shown in Figure 3a. Similar observations were
made in sequential treatment studies in NHEKs. Pretreatment
with KVDGTS diminished the subsequent response to cathespin S
whereas pretreatment with cathepsin S abolished the subsequent
response to KVDGTS (Figure 3b).
These experiments were performed at room temperature which
would not allow for receptor turnover. It is likely that exposure of
either HeLa cells or NHEKs to protease under these conditions
resulted in clearance of intact receptors. This scenario may explain
why subsequent incubation with peptides did not generate a
response.
PAR2 activation by KVDGTS stimulates second
messenger activation
To confirm that KVDGTS induces PLC activation and triggers
the ionositol phosphate (IP) cascade similar to cathepsin S or other
PAR2 agonists, we measured the generation of IP1, a downstream
metabolite of IP3 that accumulates in cells following receptor
activation. HeLa cells were transfected with PAR2 cDNA and IP1
levels were assayed following 1 hour of exposure to KVDGTS,
SLIGRL or cathepsin S. Treatment with KVDGTS and SLIGRL
produced similar levels of IP1, approximately 54 nM and 66 nM
respectively (Figure 4) after subtracting baseline values. Cathepsin
S treatment consistently generated higher levels of IP1 than either
SLIGRL or KVDGTS, 122 nM in this particular experiment, a
finding that was reproducible. This finding suggests that proteases
and their associated tethered ligands provide more efficient
activation of the receptor as compared to free hexapeptides. This
result is consistent with the observation that high or pharmacologic
concentrations of hexapeptides are needed to generate in vitro or in
vivo responses as noted in the Discussion.
PAR2 Activation by Cathepsin S
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downstream signaling cascades in HeLa cells, manifest by
phosphorylation of protein kinase C (PKC). HeLa cells were
treated with KVDGTS and Western blot analysis was performed
to determine if KVDGTS stimulated PKC phosphorylation.
KVDGTS caused an increase in the level of phosphorylation of
PKC as compared to untreated controls (Figure 5).
SLIGKVDGTS (10 mM), SLIGRL and cathepsin S (1 mM) were
also included in this analysis. The detectable levels of phosphor-
ylation were similar between KVDGTS and cathepsin S whereas
SLIGRL and SLIGKVDGTS had a weaker effect. This finding
was reproducible. This differential result suggests that KVDGTS
and SLIGRL can elicit different downstream signals following the
activation of PAR2.
Cathepsin S fails to activate mutant PAR2 while tethered
ligand hexapeptides retain activity
We next sought to determine the relevance of cathepsin S
cleavage sites identified in the synthetic N-terminal PAR2
sequence as compared to the equivalent sites in the intact
receptor. Selected point mutations were introduced near the N-
terminus of full-length PAR2 to generate 3 distinct mutant
receptors. The leucine
38 residue at the cleavage site associated
Table 1. LC/MS/MS data from cathepsin S digestion of the human PAR2 N-terminal peptide G
28TNRSSKGRSLIGKVDGTSHVTGKGVT.
P1 position Sequence Counts
VD
43GTSHVTGKGVT 4
IG
40KVDGTSHVTGKGVT 3
-G
28TNRSSKGRSL 163
-G
28TNRSSKGRSLI 9
-G
28TNRSSKGRSLIGK 4
-G
28TNRSSKGRSLIGKVD 54
-G
28TNRSSKGRSLIGKVDGTSHVT 38
-G
28TNRSSKGRSLIGKVDGTSHVTG 2
-G
28TNRSSKGRSLIGKVDGTSHVTGKGVT 343
DG
44TSHVTGKGVT 8
LI
39GKVDGTSHVT 7
LI
39GKVDGTSHVTG 7
LI
39GKVDGTSHVTGKGVT 24
GK
41VDGTSHVT 13
GK
41VDGTSHVTG 8
GK
41VDGTSHVTGK 5
GK
41VDGTSHVTGKG 1
GK
41VDGTSHVTGKGV 5
GK
41VDGTSHVTGLGVT 29
GR
36SLIGKVD 4
SS
33KGRSLIG 4
RS
32SKGRSLIG 5
GT
29NRSSKGRSLIG 4
GT
45SHVTGKGVT 3
KV
42DGTSHVT 1
KV
42DGTSHVTG 2
KV
42DGTSHVTGKGVT 4
MS/MS analysis of cathepsin S cleavage of synthetic N-terminal PAR2. Column 1 lists the amino acid in the P1 postion. Column 2 lists the identified cleaved peptide.
Column 3 lists the number of times the cleaved peptide occurred in the scan. Details of the method are provided in the Experimental Procedures section.
doi:10.1371/journal.pone.0099702.t001
Figure 1. Concentration-effect curves for PAR2 derived pep-
tides. Calcium-dependent responses were determined in PAR2-
transfected HeLa cells following incubation with the indicated peptides.
The curves for activating peptides are similar in shape although that for
KVDGTS is shifted to the right and has a lower peak calcium response as
compared to SLIGRL and SLIGKVDGTS. The inverse hexapeptides,
STGDVK and LRGILS were not active.
doi:10.1371/journal.pone.0099702.g001
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second mutant receptor, PAR2M2, was generated in which the
gylcine
40 residue associated with KVDGTS was changed to
alanine. A third mutant receptor, PAR2M3, was generated in
which the leucine
38 and glycine
40 residues were each changed to
alanines. We then introduced a Gaussia luciferase tag to the N-
terminus of PAR2 and the mutant receptors. Luciferase-tagged
receptors were transfected into HeLa cells followed by incubation
with cathepsin S. Luciferase activity was assessed in the media
(Figure 6a). While cathepsin S cleaved the native and PAR2M1
receptors, it did not cleave PAR2M2 or PAR2M3. This result
highlights the importance of the glycine
40 residue in receptor
cleavage. A western blot using an anti-luiferase antibody
confirmed the results of the luminescence assay (Figure 6b).
To complement and confirm the luciferase studies, we used
calcium imaging to investigate the effects of cathepsin S and
KVDGTS on mutant receptors. Cathepsin S induced normal
calcium responses in HeLa cells transfected with PAR2M1.
Cathepsin S did not induce calcium responses in either the
PAR2M2 or PAR2M3 mutants. These results support the critical
importance of glycine
40 for cleavage and activation by this
protease (Figure 7a). KVDGTS activated all three mutant
receptors with a calcium reponse curve similar to that of the
wildtype PAR2 receptor (Figure 7b). These data reveal that
KVDGTS activation of PAR2 does not depend on the cathepsin S
cleavage sites.
Discussion
Proteases and PARs have separately and together been
implicated in the pathogenesis of pain, itch, asthma, cardiovascu-
lar disease and numerous other conditions associated with
inflammation[4,26–28]. Serine proteases had been considered
the primary activators and inactivators of PAR2. However, recent
publications support a role for cysteine proteases as well as other
non-serine proteases in activating and regulating this recep-
tor[5,29]. We previously showed that cathepsin S, a cysteine
protease, activates PAR2 but had not identified the mechanism by
which activation occurred. In the present study, we show that the
mechanism depends upon cleavage at a specific site near the N-
terminus of PAR2. This cleavage site is distinct from that at which
serine proteases cleave.
Treatment of the synthetic N-terminus of PAR2 with cathepsin
S, followed by MS/MS sequencing, led us to evaluate two
Figure 2. PAR2 N-terminal hexapeptides are capable of activating the receptor. a) Single-cell calcium imaging in HeLa cells transfected
with PAR2 cDNA demonstrated a similar response to KVDGTS (thick solid line) and SLIGRL (thick dotted line). A weaker response was observed in
response to IGKVDG (thin solid line). HeLa cells transfected with salmon sperm DNA and stimulated with KVDGTS did not respond (horizontal dotted
line). b) Cathepsin S (solid line) and KVDGTS (100 mM) (dotted line) elicit similar calcium responses in NHEKs. KVDGTS (100 mM) and SLIGRL (10 mM),
IGKVDG (100 mM) and cathepsin S (2 mM).
doi:10.1371/journal.pone.0099702.g002
Figure 3. KVDGTS alters PAR2 response to cathepsin S. a) HeLa cells transfected with PAR2 cDNA were treated with KVDGTS and
subsequently with cathepsin S after a 2 minute interval (dotted line). Pre-treatment with KVDGTS attenuates the response to cathepsin S. HeLa cells
treated with cathepsin S failed to respond subsequently to KVDGTS (100 mM) (solid line). b) KVDGTS (100 mM) elicted calcium responses in NHEKs and
the subsequent response to cathepsin S (2 mM) was attenuated. Treatment with cathepsin S abolishes the response to the subsequent addtion of
KVDGTS. The second agent was delivered at the 300 second timepoint. KVDGTS (100 mM), cathepsin S (2 mM).
doi:10.1371/journal.pone.0099702.g003
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only two residues. Substitution mutants were generated at each site
individually and together. The single substitution mutant closest to
the N-terminus retained activity in response to cathepsin S. The
single substitution mutant only two residues away was unrespon-
sive to cathepsin S, as was the double mutant. Mutants that could
not be cleaved by cathepsin S failed to generate downstream
signaling. KVDGTS, the hexapeptide corresponding to the
tethered ligand generated by cleavage at the distal site, activates
wildtype and all three mutant PAR2 receptors. We conclude that
cathepsin S cleavage of PAR2 generates a tethered ligand that
activates the receptor. KVDGTS is distinct from SLIGRL, the
conventional tethered ligand generated by serine proteases.
SLIGRL is derived from the sequence of mouse PAR2 and the
last two residues of the human equivalent, SLIGKV, are the first
residues in KVDGTS. As reported here, the decapeptide
SLIGKVDGTS, which encompasses SLIGKV and KVDGTS,
had activity comparable to that of SLIGRL.
In this report, cathepsin S cleavage was most frequent after
glycine followed by leucine. The KVDGTS sequence is preceded
by LIG, placing G
40 in the P1 postion and L
38 in the P3 postion.
The finding of cleavage after glycine is consistent with what is
reported in the MEROPS database and a recent report on
proteomic identification of protease cleavage sites (PICS)[25].
These reports reveal that cleavage after leucine at P3 is associated
with cathepsin S, but less so than with glycine at P1. Correlations
were otherwise weak between these reports and the cleavage sites
identified here. Cathepsin S rarely cleaves after alanine according
to the PICS report. We were able to take advantage of this
observation and demonstrated the importance of the glycine
40
residue to the activation of PAR2 by cathepsin S. Substitution of
glycine
40 or both glycine
40 and Leucine
38 with alanine prevented
cathepsin S from cleaving or otherwise activating PAR2.
Proteases can activate PARs but it has been hypothesized that
they can also inactivate them. Consistent with this hypothesis,
several studies have demonstrated that some proteases are capable
of ‘disarming’ PARs by cleaving at specific sites downstream of the
tethered ligand, thereby preventing subsequent activation by other
proteases such as thrombin or trypsin[30–33]. Serine proteases
including trypsin, mast cell tryptase and tissue kallikreins 5, 6 and
14 cleave PAR2 primarily following arginine residues[25,31]. As
the cathepsin S cleavage sites identified here are downstream of
the site associated with SLIGRL or SLIGKV, it is possible that
cathepsin S-induced proteolysis of PAR2 may remove cleavage
targets of these and other circulating proteases. Likewise, more
distal cleavage by serine proteases could inhibit cathepsin S
cleavage. Together, proteases, be they serine or cysteine, may
function as both direct activators and as modulators of PAR2. The
presence of inhibitors, such as cystatin, could provide an additonal
degree of homeostasis.
Based on the sequences of cathepsin S-induced cleavage
products of PAR2, we synthesized KVDGTS. KVDGTS was
capable of stimulating intracellular signaling cascades and calcium
mobilization downstream of PAR2 activation in keratinocytes as
well as in a heterologous cell line. We note that the kinetics of the
calcium transients were somewhat different between cathepsin S
and the peptides. These results may reflect what has previously
been described as ‘functional selectivity’ or ‘biased agon-
ism’[29,34] in which different proteases or synthetic peptide
ligands elicit distinct signaling responses through the activation of
the same PAR. Ligand activation of PARs is thought to induce
conformational changes within transmembrane helices that expose
cytoplasmic domains necessary for interaction with heterotrimeric
G protein subunits, which then signal to various effectors to
promote diverse cellular responses[35,36]. Protease cleavage may
result in other conformational changes that alter the exposure of
cytoplasmic domains relevant to signal transduction as compared
to activation by binding of hexapeptide ligands alone. Although
cathepsin S was effective at a concentration of 1–2 mM in these
studies, suggesting weaker activtity as compared to trypsin, it is
possible that the technical challenges in producing recombinant
cathepsin S may result in material that is less active than naturally
produced cathepsin S. SLIGRL and KVDGTS needed to be
present at substantially higher concentrations in order to
demonstrate activity. It is not clear why KVDGTS was active at
100 mM whereas SLIGRL was active at 10 mM. We caution
against attributing much significance to this observation, as it may
reflect a pharmacologic rather than a physiologic phenomenon.
Figure 4. Cathepsin S and hexapeptide agonists increase the
concentration of inositol phosphate. IP1 is a downstreatm
metabolite of IP3. IP1 concentrations were measured following
treatment with cathepsin S, KVDGTS and SLIGRL in HeLa cells that
had been transfected with PAR2 cDNA. Hexapeptide agonists activated
this signaling cascade downstream of PAR2, but to a lesser extent than
cathepsin S. Cathepsin S had no effect above baseline IP1 levels on
salmon sperm transfected cells. Cathepsin S (1 mM), KVDGTS (100 mM)
and SLIGRL (10 mM).
doi:10.1371/journal.pone.0099702.g004
Figure 5. Cathepsin S and PAR2 peptide agonists induce PKC
Ser660 phosphorylation in HeLa cells. The Western blot was
performed on HeLa cells that had been transfected with PAR2 cDNA.
Treatments included SLIGRL (lane 1), SLIGKVDGTS (lane 2), KVDGTS
(lane 3) and cathepsin S (lane 4). Non-transfected HeLa cells treated
with SLIGRL (10 mM) (lane 5) and PAR2-transfected but untreated HeLa
cells (lane 6) served as controls. SLIGRL (10 mM), SLIGKVDGTS (10 mM),
KVDGTS (100 mM) and cathepsin S (1 mM).
doi:10.1371/journal.pone.0099702.g005
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as a positive control in mM concentrations[37].
We have identified a new peptide ligand generated by cathepsin
S cleavage of PAR2. These data underscore the potential
importance of a role for cysteine proteases in mediating
physiologic or pathophysiologic conditions including inflammation
via effects on PAR2 activation or inactivation. Our findings
support a mechanism by which an N-terminal tethered ligand
generated by cathepsin S cleavage might propagate PAR2
signaling in keratinocytes, or other target cells, surrounding a
Figure 6. Cathepsin S cleavage of the PAR2 N-terminus requires glycine
40. a) Luciferase luminescence was measured after cathepsin S
(2 mM) treatment of HeLa cells expressing luciferase-PAR2 (bar 1), PAR2M1 (bar 2), PAR2M2 (bar 3), and PAR2M3 (bar 4). Luminescence of the
transfected cells without cathepsin S treatment was subtracted from each of the measurements. b) Western blots were performed on supernatants of
luciferase-PAR2 and PAR2 mutant-transfected HeLa cells following treatment with cathepsin S. Luciferase-PAR2, cathepsin S(2) (lane 1); luciferase-
PAR2, cathepsin S (+) (lane 2); PAR2M1, cathepsin S (2) (Lane 3); PAR2M1 cathepsin S (+) (lane 4); PAR2M2, cathepsin S (2) (lane 5); PAR2M2,
cathepsin S (+) (lane 6); PAR2M3, cathepsin S (2) (lane 7); PAR2M3, cathepsin S (+) (lane 8) and non-transfected HeLa cells, cathepsin S (+) (lane 9).
Molecular weight markers on the left side of the blot are in kDa.
doi:10.1371/journal.pone.0099702.g006
Figure 7. Cathepsin S fails to activate mutant PAR2 but KVDGTS retains activity on mutant PAR2. a) Calcium imaging was performed in
HeLa cells transfected with native or mutant PAR2 receptors following treatment with cathepsin S. Cathepsin S (2 mM) was able to stimulate native
PAR2 and PAR2M1 but not PAR2M2 or PAR2M3. b) In contrast, KVDGTS activated PAR2 and all three substitution mutants. Cathepsin S (2 mM),
KVDGTS (100 mM).
doi:10.1371/journal.pone.0099702.g007
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cutaneous inflammation could be as follows: IFN-c, a mediator of
inflammation, is a potent inducer of cathepsin S in keratino-
cytes[38], the production of which could lead to PAR2 activation
followed by itch and pain.
The observation that pretreatment with KVDGTS attenuated
responses to cathepsin S, and vice versa, raises the possibility that
endogenously generated extracellular peptides may limit PAR
activation in response to cathepsin S, or other proteases, in the
setting of inflammation in vivo. The presence of N-terminal peptide
fragments may influence downstream recruitment of second
messengers due to biased agonism, triggering distinct cellular
responses to different degrees or types of inflammation. While
PAR cleavage by proteases such as trypsin may be important in
regulating PAR-associated processes, it is possible that PAR
cleavage by a number of proteases, including cysteine and serine
proteases, may contribute to the complexity of receptor regulation.
Zymogen activation of proteases, endogenous protease inhibitors,
peptide activation, cleavage by several classes of proteases at
distinct sites and differential activation of downstream signaling
pathways may all participate in the process of PAR activation and
modulation.
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